Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Resyca
Deal Size : Undisclosed
Deal Type : Partnership
Silo, Resyca Partner on Intranasal IND Study of PTSD Drug SPC-15
Details : Silo has partnered with Resyca for a drug-device study of the formulation-specific, microchip-based nasal spray system used in its lead asset, SPC-15 an intranasal prophylactic treatment for PTSD.
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Resyca
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Frontage Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Silo Pharma Starts Key Safety Study for PTSD Drug SPC-15 at Frontage Labs
Details : The agreement aims for a FDA requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 14, 2025
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Frontage Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Details : SP-26 is a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Doses First Patient in IND-Enabling PTSD Study for SPC-15
Details : SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety.
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Reports Positive SP-26 Study for Chronic Pain & Fibromyalgia
Details : SP-26 is a ketamine HCl-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Initiates Pharmacokinetic Study for SP-26 in Chronic Pain, Fibromyalgia
Details : SP-26 (ketamine) is a NMDA receptor modulator, small molecule drug candidate, which is currently being evaluated in preclinical studies for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Achieves Positive Outcomes in SP-26 Ketamine Implant Testing
Details : SP-26 is a ketamine HCl-based injectable dissolvable polymer implant beng investigated for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 31, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Completes FDA Pre-IND Meeting for SPC-15 Development in PTSD
Details : SPC-15 IS a 5-HT4 receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of patients with post-traumatic stress disorder.
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Sever Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Silo Pharma Expands Agreement with Sever Pharma for Ketamine Implant Therapeutic
Details : The agreement aims for scale-up extrusion of the Company’s SP-26, a ketamine-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 14, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Sever Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Resyca BV Partner
Deal Size : Undisclosed
Deal Type : Partnership
Silo Pharma and Resyca BV Partner on Device and CMC Development for PTSD Drug SPC-15
Details : The partnership aims to advance the development of Silo lead product SPC-15, a 5-HT4 receptor agonist, which is being evaluated for the treatment of post-traumatic stress disorder.
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2024
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Resyca BV Partner
Deal Size : Undisclosed
Deal Type : Partnership